GSK’s top exec sees ‘good progress’ but drug giant forecasts decline in earnings
Drug giant GlaxoSmithKline is “making good progress” as it revamps under CEO Emma Walmsley but earnings will likely take a hit this year due to increased competition for its asthma big seller Advair.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
